Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

Journal of Personalized Medicine

Wen-Shuo Wu¹ 

[1] Department of Chest Medicine, Taipei Veteran General Hospital, Yang-Min National University, No. 21, Sec. 2, Shi-Pai Rd., Taipei 11217, Taiwan; E-Mail

关键词: epidermal growth factor receptor (EGFR);    tyrosine kinase inhibitor (TKI);    non-small cell lung cancer (NSCLC);   

DOI  :  10.3390/jpm4030297

来源: mdpi

【 摘 要 】

In the era of personalized medicine, epidermal growth factor receptor (EGFR) inhibition with tyrosine kinase inhibitor (TKI) has been a mainstay of treatment for non-small cell lung cancer (NSCLC) patients with an EGFR mutation. Acquired resistance, especially substitution of methionine for threonine at position 790 (T790M), which has accounted for more than half of the cases, developed inevitably in patients who were previously treated with EGFR-TKI. At present, there is no standard treatment for patients who have developed a resistance to EGFR-TKI. Several strategies have been developed or suggested to treat such patients. This article aimsto review the EGFR-TKI re-treatment strategy and the efficacy of different generations of EGFR-TKIs in patients with acquired resistance to prior EGFR-TKI.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.